Related Experiment Videos
[Iris metastases in breast carcinoma]
R Neitzke1, C W Spraul, G E Lang
1Universitätsklinikum Ulm. roland.neitzke@lycos.com
Summary
Metastatic breast carcinoma rarely affects the iris. Positron-emission tomography aids in diagnosing iris metastasis and planning treatment for this rare condition.
Area of Science:
- Ophthalmology
- Oncology
- Medical Imaging
Background:
- Metastatic cancer of the iris is an infrequent clinical presentation.
- Breast carcinoma is a known primary source for rare iris metastases.
Observation:
- A 60-year-old woman with a history of breast carcinoma developed iris lesions five years post-diagnosis.
- Diagnostic imaging included slit-lamp examination, ultrasound biomicroscopy, positron-emission tomography, and fluorescein angiography.
Findings:
- Iris metastasis presented as whitish-pink nodules with chamber angle infiltration and high vascularity.
- Positron-emission tomography identified widespread metastatic disease, including the iris, liver, lungs, bones, and lymph nodes.
- Literature review confirmed breast carcinoma as a rare cause of iris metastasis, typically presenting as inferior iris clumps.
Implications:
- Positron-emission tomography is a sensitive tool for detecting metastatic lesions and guiding therapeutic strategies.
- Treatment options for isolated iris metastasis include radiation therapy, argon laser treatment, and block excision.
- Early detection and comprehensive staging are crucial for managing rare metastatic iris lesions from breast cancer.